A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumors Clinical Trial

Official title:

A First-in-Human Phase I Study of ATG-031 in Patients With Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06028373
• Other study ID #: ATG-031-001
• Status: Recruiting
• Phase: Phase 1
• Start date: December 8, 2023
• Est. completion date: June 30, 2026

Study information

• Verified date: March 2024
• Source: Antengene Corporation
• Contact: Ashley Liu
• Phone: 0431292256
• Email: ting.liu[@]antengene.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D（Refered Phase II dose） of ATG-031.

Description:

This is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase. Dose Escalation Phase: approximately 30-48 patients . Dose Expansion Phase: the number of patients enrolled will depend on the number of disease cohorts to be expanded and data observed in the Dose Escalation Phase.The Dose Escalation Phase will enroll patients with advanced solid tumors. Based on data from dose escalation (e.g., adverse events [AEs], dose-limiting toxicity [DLT], efficacy data, pharmacodynamic [PDx] data, or pharmacokinetic [PK] data), the Dose Expansion Phase will enroll patients with selected advanced solid tumors or B-NHL.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: June 30, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

1. Histological or cytologically confirmed advanced solid tumor or B-NHL which have relapsed from or been refractory to all locally available standard therapies.

2. Adequate hepatic function:

1. AST and ALT = 2.5×times ULN (= 5 × ULN if liver metastases).

2. Total bilirubin = 1.5×ULN (except Gilbert syndrome).

3. Lipase and amylase = 2×ULN.

3. Adequate renal function: calculated creatinine clearance of = 40 mL/min using the Cockroft- Gault formula.

4. Adequate bone marrow function without growth factors or blood transfusion within 7 days of the first dose of study treatment.

1. Absolute neutrophil count (ANC) = 1.5×109/L.

2. Platelet count = 100×109/L.

3. Hemoglobin = 90 g/L.

Key Exclusion Criteria:

1. Patients with CNS malignancies, except those who are clinically stable for = 4 weeks and off corticosteroids following prior surgery, whole-brain radiation, or stereotactic radiosurgery.

2. Received any other investigational product or prior systemic anticancer therapy including chemotherapy, immunotherapy, radiotherapy, or other anticancer within 21 days prior to first dose of study

3. Grade =3 irAEs or irAEs that lead to discontinuation of prior immunotherapy.8. Other primary malignancies developed within 5 years prior to the first dose of the study treatment

4. Other primary malignancies developed within 5 years prior to the first dose of the study treatment

5. Have active or previous autoimmune diseases that are likely to recur or are at risk of such diseases judged by the investigator.

6. Major cardiovascular disease

7. Active hepatitis B and/or hepatitis C (HBV-DNA or HCV-RNA detectable by local laboratory, respectively).

8. Patients with history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).

9. A history of allograft organ transplantation for solid tumor or allogeneic hematopoietic stem cell transplantation for B-NHL patients).

10. Patients who are pregnant or lactating.

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin

Intervention

Drug:
• ATG-031
ATG-031 will be infused Q3W on Day 1 of each cycle, at the starting dose of 0.03 mg/kg and a maximum dose of 9 mg/kg in the Dose Escalation Phase, and the defined MTD if available or OBD in the Dose Expansion Phase. Based on the emerging PK, PDx, safety, and other relevant data, SRC may decide to explore alternative dosing schedules.

Locations

Country	Name	City	State
United States	Regents of the University of Colorado	Aurora	Colorado
United States	University of Texas M.D. Anderson Cancer Center	Houston	Texas
United States	Yale University	New Haven	Connecticut
United States	University of California San Francisco (UCSF)	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Antengene Biologics Limited

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AE	Evaluate the safety and tolerability of ATG-031	90 days after last dose of treatment
Primary	DLT	Evaluate the safety and tolerability of ATG-031	at the end of cycle 2 ( each cycle is 21 days)
Primary	RP2D	RP2D will be determined based on safety, tolerability, PK, and preliminary efficacy data	at the end of dose escalation, about 1 year